Previous 10 | Next 10 |
Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...
Amylyx Pharmaceuticals Inc. (AMLX) is expected to report $0.42 for Q3 2023
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) will report its third quarter 2023 financial results on Thursday, November 9, 2023. Amylyx’ senior management team will host a conference call and audio webcast at 8:00 a.m. ET to discuss th...
- ORION is a randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating the safety, efficacy, and tolerability of AMX0035 in adults with PSP - Study anticipates enrolling approximately 600 participants globally, with trial initiation anticipated by the end of 2023 ...
2023-10-19 08:15:00 ET Biotech stocks have been beaten down in 2023, with the sector off nearly 4% this year while the S&P 500 is up more than 15%. But some of the larger, better known biotech stocks have thrived -- Vertex Pharmaceuticals , Regeneron Pharmaceuticals , an...
2023-10-13 08:27:23 ET More on Momentus, Phio Pharmaceuticals, etc. Momentus Inc. (MNTS) Q2 2023 Earnings Call Transcript Wheeler REIT: Gearing Up For Sharemageddon Momentus to provide orbital delivery services for RIDE! Space Momentus prices $5M stock offeri...
- PHOENIX Phase 3 trial topline results on track for mid-2024 and will inform regulatory next steps in the EU - Final decision from the European Commission expected by the end of 2023 Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Comp...
Results demonstrated a 10.4 month difference in overall survival and a 52% lower risk of death over the duration of the follow-up period Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the publication of a post hoc ...
L’Agence Nationale de Sécurité du Médicament et des produits de santé (ANSM), the national authority for authorizing medicinal products in France, has granted “accès compassionnel” (compassionate access) to AMX0035 (sodium phenylbutyrate and ursodoxic...
Topics include safety data from the AMX0035 U.S. Expanded Access Program, progress on the development of an ALS diagnostic biomarker test, new in vitro data on AMX0114, and more Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today...
News, Short Squeeze, Breakout and More Instantly...
Amylyx Pharmaceuticals Inc. Company Name:
AMLX Stock Symbol:
NASDAQ Market:
Amylyx Pharmaceuticals Inc. Website:
- Avexitide is a novel, first-in-class GLP-1 receptor antagonist with the potential to treat hyperinsulinemic hypoglycemia - FDA Breakthrough Therapy Designation granted for avexitide for post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism - Acquisition builds on Am...
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced that Amylyx’ management team will host a conference call and webcast tomorrow, Wednesday, July 10, 2024, at 8:00 a.m. ET to discuss the acquisition of avexitide from Eiger ...
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that management will participate in a fireside chat presentation at the Goldman Sachs 45th Annual Global Healthcare Conference. The conference is being conducted in-person in Miam...